Want to see AU:ADO full AI Analyst Report?
Top Page
AnteoTech Ltd
(Sydney:ADO)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.02
▲(15.00% Upside)
Action:Upgraded
Date:09/06/26
The score is primarily constrained by weak financial performance—volatile and shrinking revenue in FY2026, continued large losses, and persistent negative operating/free cash flow—despite relatively modest leverage. Technicals add only limited support with generally weak momentum (low RSI, negative MACD) and no clear trend. Valuation is not compelling due to negative earnings (negative P/E) and no dividend yield provided.
Positive Factors
Platform breadth
AnteoTech’s surface chemistry platform addresses both diagnostics and energy storage applications, giving the company multiple potential routes to commercialisation. This breadth can support longer-term resilience if adoption develops unevenly across end markets, while shared technology capabilities may enable reuse across products.
Negative Factors
Sharp revenue contraction
A sharp fall in already-small and volatile revenue weakens evidence of sustained customer adoption and commercial scale. Without consistent top-line expansion, fixed development and operating costs are harder to absorb, making a durable path toward profitability and internally funded growth more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform breadth
AnteoTech’s surface chemistry platform addresses both diagnostics and energy storage applications, giving the company multiple potential routes to commercialisation. This breadth can support longer-term resilience if adoption develops unevenly across end markets, while shared technology capabilities may enable reuse across products.
Read all positive factors
AnteoTech Ltd (ADO) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$78.23M
Dividend YieldN/A
Average Volume (3M)8.31M
Price to Earnings (P/E)―
Beta (1Y)1.83
Revenue Growth-51.74%
EPS Growth32.00%
CountryAU
Employees224
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,259,767,300
10 Day Avg. Volume5,155,918
30 Day Avg. Volume8,313,181
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)6.74
Price to Sales (P/S)170.19
P/FCF Ratio-22.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AnteoTech Ltd Business Overview & Revenue Model
Company Description
AnteoTech Limited develops, manufactures, commercializes, and distributes products for clean energy technology and life science markets primarily in Australia, Asia, Europe, and North America. The company’s products include AnteoBind, a metal-ion ...
AnteoTech Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
24
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 467.59K | 968.88K | 460.40K | 365.72K | 760.88K |
| Gross Profit | 0.00 | 968.88K | 460.40K | 365.72K | 760.88K |
| EBITDA | -6.38M | -7.96M | -11.57M | -12.35M | -12.07M |
| Net Income | -4.93M | -6.76M | -8.88M | -12.65M | -10.72M |
Balance Sheet | |||||
| Total Assets | 15.40M | 6.45M | 9.38M | 5.36M | 15.26M |
| Cash, Cash Equivalents and Short-Term Investments | 11.20M | 2.34M | 5.03M | 2.72M | 10.10M |
| Total Debt | 2.15M | 1.96M | 2.31M | 1.31M | 1.03M |
| Total Liabilities | 3.60M | 3.30M | 4.08M | 2.99M | 2.91M |
| Stockholders Equity | 11.80M | 3.15M | 5.31M | 2.38M | 12.36M |
Cash Flow | |||||
| Free Cash Flow | -3.58M | -6.05M | -7.58M | -8.77M | -11.77M |
| Operating Cash Flow | -3.53M | -5.83M | -6.52M | -8.08M | -8.65M |
| Investing Cash Flow | -5.55M | -174.87K | -1.06M | -690.83K | -3.12M |
| Financing Cash Flow | 12.45M | 3.32M | 9.89M | 1.39M | 482.29K |
AnteoTech Ltd Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.02
Negative
0.02
Positive
Market Momentum
>-0.01
Negative
38.54
Neutral
64.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ADO, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 38.54 is Neutral, neither overbought nor oversold. The STOCH value of 64.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ADO.
AnteoTech Ltd Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
58 Neutral | AU$5.52B | 120.19 | 7.11% | ― | 26.66% | 179.32% | |
49 Neutral | AU$379.26M | -46.20 | -42.35% | ― | 145.32% | 25.75% | |
45 Neutral | AU$846.89M | -8.24 | -51.15% | ― | ― | -44.83% | |
44 Neutral | AU$78.23M | -18.33 | -71.28% | ― | -51.74% | 32.00% | |
43 Neutral | AU$24.81M | -2.15 | -93.66% | ― | -23.71% | -16.02% | |
42 Neutral | AU$43.38M | -0.58 | -144.24% | ― | -23.82% | 12.36% |
* Basic Materials Sector Average
AU:ADO
AnteoTech Ltd
0.02
>-0.01
-8.70%
AU:SPL
Starpharma Holdings Limited
0.81
0.69
569.42%
AU:TLX
Telix Pharmaceuticals
16.50
2.68
19.39%
AU:CU6
Clarity Pharmaceuticals Ltd.
2.37
-0.73
-23.55%
AU:PIQ
Proteomics International Laboratories Ltd.
0.15
-0.18
-54.69%
AU:RAD
Radiopharm Theranostics Limited
0.01
-0.02
-65.52%
AnteoTech Ltd Corporate Events
AnteoTech Issues Shares Under Short-Term Incentive Plan After KPI Review
Sep 1, 2026
AnteoTech has completed its FY2026 annual staff and executive performance review, concluding that 70.9% of company-wide KPIs were achieved in line with its ongoing commercialisation strategy. In recognition, the board approved the issuance of appr...
AnteoTech plans equity placement of 5.5 million new shares
Sep 1, 2026
AnteoTech Ltd has notified the Australian Securities Exchange of a proposed placement involving up to 5,544,884 ordinary fully paid shares. The company expects to issue the new securities on 15 September 2026, subject to ASX processes and listing ...
AnteoTech Narrows Loss as Cost Cuts and Fresh Capital Strengthen Balance Sheet
Aug 31, 2026
AnteoTech Ltd reported a narrower full-year loss of $4.93 million for the year to 30 June 2026, down 27% from the prior year, as cost reductions offset weaker operating revenue. Revenue from ordinary activities fell 52% to $0.47 million, though to...
AnteoTech Refreshes Securities Trading Policy to Bolster Governance
Aug 26, 2026
AnteoTech Limited has updated its Securities Trading Policy, effective 26 August 2026, signalling a refresh of its governance framework around share dealing by insiders. The revised policy, released to the market and made available on the company&...
AnteoTech triples life sciences sales pipeline after ADLM 2026
Aug 24, 2026
AnteoTech reported a significant expansion of its Life Sciences sales pipeline following its attendance at the ADLM 2026 diagnostics and laboratory medicine conference in Anaheim. The company engaged with diagnostic test and particle manufacturers...
AnteoTech Advances CLIA Collaboration and Prepares New Diagnostic Kit Launch
Jul 1, 2026
AnteoTech has completed the initial stage of a collaborative CLIA product development program, validating its AnteoBind NXT activated magnetic particles for use on large-scale automated diagnostic platforms and recognising A$61,595 in related reve...
AnteoTech advances battery push with launch of PFAS-free Anteo C primer additive
Jun 30, 2026
AnteoTech has launched Anteo C, a new cross-linker performance additive for primer coatings on copper and aluminium current collectors in lithium-ion batteries, and moved it from lab-scale evaluation to manufacturing-scale trials with a 20-litre s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.